Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2022-10-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
第三届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the company's board meeting held on October 24, 2022. It specifically mentions the approval of the 2022 third quarter report but does not contain the report itself or detailed financial data. The document is short (587 characters) and states that the detailed report can be found on the designated disclosure website. This fits the pattern of a Board/Management Information announcement about board meeting decisions rather than the actual Interim/Quarterly Report. Therefore, the correct classification is Board/Management Information (MANG).
2022-10-24 Chinese
第三届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the Supervisory Board meeting of Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It specifically mentions the approval of the company's 2022 third quarter report by the Supervisory Board, confirming the report's compliance and accuracy. The document itself is not the quarterly report but an announcement of the meeting resolution and approval of that report. The document length is short (622 characters), and it serves as a meeting resolution announcement rather than containing substantive financial data or the full report. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of a supervisory board meeting resolution regarding the quarterly report, not the report itself.
2022-10-24 Chinese
2022年三季度报告（更新前）
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 Third Quarter Report" of Xiamen Aide Biomedical Technology Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the third quarter of 2022. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (third quarter). The presence of comprehensive financial statements and analysis for a quarterly period aligns with the definition of an Interim / Quarterly Report (IR). The document length is substantial (over 14,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2022
2022-10-24 Chinese
关于与百济神州达成靶向药物临床研究合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a cooperation agreement between the company and another biotech firm for clinical research collaboration. It includes details about the agreement, parties involved, and impact on the company, but does not contain financial statements, audit information, or detailed financial results. It is a regulatory announcement about a business cooperation event, not a financial report or management discussion. The document length is short (1632 characters), and it is a formal public disclosure of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-11 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulatory guidelines, and future intentions to continue the repurchase. It references a previously disclosed repurchase report and provides updates on the repurchase activity. The document length is short (1322 characters) and it is not a full financial report but an update on share buyback activity. Therefore, it fits the category of Transaction in Own Shares (POS).
2022-10-10 Chinese
关于转让SDC2产品权益及子公司艾之维股权的进展公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the progress of a transaction involving the transfer of product rights and subsidiary equity. It details the transaction overview, progress, payment schedule, and related documents. There is no financial report, earnings data, or regulatory certification. The content fits the description of a Capital/Financing Update as it relates to company fundraising and capital structure changes through asset and equity transfer. The document length is short and it is not an announcement of a report publication but a substantive update on a financing-related transaction.
2022-09-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.